

Specialised Commissioning continues to be an issue of significance and uncertainty for both industry and the NHS. What do the latest reports of regional push back on the plans for devolution to ICBs mean?
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?
What is IDAP? As the IDAP pilot opens, we explore how this new pathway offers a fast-track route to patient access for innovative medical technologies.
Ahead of our NHS Transformation Symposium, former Pharma UK Market Access Director, Richard Marsh offers his thoughts on transforming the NHS.
As our developers experiment with integrating AI into our tools, we demonstrate the potential (and current limitations) of this technology with ChatGPT